Ascendis Pharma price target raised to $280 from $275 at RBC Capital
RBC Capital raised the firm's price target on Ascendis Pharma to $280 from $275 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up considerable momentum, with a near-unprecedented two-week move in June relative to the S&P